# EU-1-13-905_public-assessment-report_20140317_20140317_izba-epar-public-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
SCIENCE
MEDICINES HEALTH
19 December 2013
EMA/13480/2014
Committee for Medicinal Products for Human Use (CHMP)
Assessment report
Izba
International non-proprietary name: travoprost
Procedure No. EMEA/H/C/002738/0000
Note
Assessment report as adopted by the CHMP with all information of a commercially confidential
nature deleted
7 Westferry Circus . Canary Wharf . London E14 4HB . United Kingdom
Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455
E-mail info@ema.europa.eu Website www.ema.europa.eu
An agency of the European Union
Product information
Name of the medicinal product:
Izba
Applicant:
Alcon Laboratories (UK) Ltd
Frimley Business Park
Frimley
Camberley
GU16 7SR
UNITED KINGDOM
Active substance:
travoprost
International Nonproprietary Name:
travoprost
Pharmaco-therapeutic group
(ATC Code):
Therapeutic indication(s):
Decrease of elevated intraocular pressure in
adult patients with ocular hypertension or
open-angle glaucoma
Pharmaceutical forms:
Eye drops, solution
Strengths:
30 ug/ml
Routes of administration:
Ocular use
Packaging:
bottle (PP)
Package sizes:
1 bottle and 3 bottles
Travoprost
(S01EE04)
Izba Assessment Report
EMA/13480/2014
Page 2/62
